Recent news coverage primarily relates to broader pharmaceutical industry developments and does not directly report new material events specific to Amarin. The latest earnings call transcript and earnings reports provide insights into financial performance and operational updates.

• Amarin held its Q2 2026 earnings call, discussing financial results and operational highlights [N6].
• The company reported Q2 2026 earnings with revenues falling short of expectations but earnings exceeding estimates [N8].
• Amarin's Q2 earnings call highlighted ongoing commercialization efforts and challenges [N8][N6].

Amarin's established patent portfolio and ongoing litigation efforts could sustain exclusivity for VASCEPA, supporting continued revenue generation. The company's strong liquidity position provides financial flexibility to support commercialization and research activities. Successful defense of intellectual property rights and effective market penetration of VASCEPA could enhance its commercial prospects. The company's focus on cardiovascular risk reduction addresses a significant medical need, potentially supporting demand for its product.

Patent litigation outcomes are uncertain and could result in loss of exclusivity or increased competition from generics, negatively impacting revenues. The company has a history of operating losses and may continue to incur significant expenses related to litigation, research, and commercialization. Risks from cybersecurity breaches, product liability claims, and customer concentration could disrupt operations or financial performance. Changes in tax residency or laws could adversely affect profitability. Failure to attract and retain key personnel may hinder business execution.

Amarin's moat is primarily based on its intellectual property portfolio protecting VASCEPA/VAZKEPA, including issued patents and pending applications, as well as trade secrets and know-how. The company actively enforces its patents through litigation to defend against generic competition. The specialized nature of its product and regulatory approvals also contribute to barriers to entry. However, the pharmaceutical industry is highly competitive, and patent challenges or successful generic entries could erode market share. The company's ability to maintain patent protection and commercialize effectively underpins its competitive advantage.

• Patent Litigation Risk: Ongoing patent infringement lawsuits are costly and outcomes are uncertain, with potential for loss of exclusivity or invalidation of patents protecting VASCEPA.
• Generic Competition: Competitors may design around patents or gain approval for generic or branded competitive products, which could materially reduce revenue potential.
• Financial Losses and Profitability: The company has a history of operating losses and an accumulated deficit, with profitability dependent on successful commercialization of VASCEPA.
• Cybersecurity Threats: Amarin faces risks from cyberattacks and data breaches that could disrupt operations or lead to regulatory actions and reputational damage.
• Customer Concentration: A significant portion of sales is concentrated among a few large pharmaceutical wholesalers, posing risks if relationships deteriorate.
• Product Liability: Potential product liability claims related to VASCEPA or clinical trials could have material adverse effects.
• Tax Residency Uncertainty: Changes in tax residency or tax laws could negatively impact future profitability and tax obligations.
• Key Personnel Dependence: Loss of senior management or difficulty attracting qualified personnel could disrupt business operations and execution.

• Amarin Corp PLCUK is a pharmaceutical company focused on the commercialization of VASCEPA/VAZKEPA (icosapent ethyl), a drug approved for reducing cardiovascular risk.
• The company has been generating product revenue from sales of VASCEPA since January 2013.
• Amarin is engaged in ongoing patent litigation to protect its intellectual property rights related to VASCEPA, including a notable lawsuit against Hikma involving patent infringement claims.
• The patent litigation process is costly, time-consuming, and outcomes are uncertain, with recent appeals and Supreme Court involvement noted.
• Amarin relies on a combination of issued patents, pending patent applications, trade secrets, and know-how to protect its competitive position.
• The company faces competition from generic drug manufacturers and branded competitors potentially designing around its patents.
• Amarin has a history of operating losses and an accumulated deficit of approximately $1.7 billion as of December 31, 2025.
• The company reported net losses for fiscal years 2023, 2024, and 2025, with significant expenses related to research, development, and commercialization.
• Amarin's ability to achieve sustained profitability depends on market acceptance and commercial success of VASCEPA and effective manufacturing and marketing.
• As of September 30, 2026, Amarin reported cash and cash equivalents of $156.5 million and short-term investments of $166.9 million, with current assets of $612.9 million and current liabilities of $175.1 million, resulting in a current ratio of 3.5 and a cash ratio of 1.85.
• The company reported a net income of $245,000 for the quarter ended September 30, 2026, with basic and diluted EPS of $0.00.
• Amarin is subject to risks including patent litigation costs, potential generic competition, cybersecurity threats, product liability claims, customer concentration risk, and tax residency uncertainties.
• The company has disclosed risks related to loss of key personnel and the challenges of attracting and retaining qualified scientific and management staff.
• Amarin's internal and third-party computer systems face cybersecurity risks that could disrupt operations or lead to data breaches.
• The company has a significant concentration of sales to a few large pharmaceutical wholesalers, which poses customer concentration risk.
• Recent earnings calls and reports indicate ongoing efforts to manage commercialization and operational challenges.
• Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.